Ticarcillin-Clavulanic Acid Pharmacokinetics in Preterm
|
|
- Brett Arnold
- 5 years ago
- Views:
Transcription
1 ANTiMIROBLAL AGENTS AND HEMOTHERAPY, Sept. 199, p. -8 Vol. 38, No /9/$.+ opyright 199, American Society for Microbiology Ticarcillin-lavulanic Acid Pharmacokinetics in Preterm Neonates with Presumed Sepsis AARON H. BURSTEIN,'* LANE E. WYBLE, PETER GAL,3' PHILIP R. DIAZ,3' J. LAURENE RANSOM, RITA Q. ARLOS, AND ALAN FORREST' Division of Neuropharnnacology, Dent Neurologic Institute, Millard Fillmore Hospital, Buffalo, New York 191; Department of Pediatrics, University of South Florida ollege of Medicine, Tampa, Florida 3366; Greensboro Area Health Education enter, The Moses H. one Memorial Hospital3 and The Women's Hospital of Greensboro, Greensboro, North arolina; and enter for linical Pharmacy Research, School of Pharmacy, The State University of New York at Buffalo, Buffalo, New York 165 Received 1 January 199/Returned for modification 1 April 199/Accepted 6 June 199 The objective of the reported study was to characterize the pharmacokinetics of ticarcillin and clavulanic acid in premature low-birth-weight (less than, g) neonates with presumed sepsis. Eleven infants received 1 courses of ticarcillin-clavulanic acid at 75 mg/kg of body weight intravenously every 1 h. Blood samples were collected at.5, 1.5,, and 8 h following the infusion of the initial dose. The concentrations of ticarcillin and clavulanic acid were determined by a microbiologic assay. Median (interpatient coeflicients of variation) values for the volume of the central compartment, total steady-state volume, distributional clearance, total clearance, and terminal elimination half-life for ticarcillin were.3 liter/kg (1%),.6 liter/kg (8%),.1 liter/h/kg (7%),.7 liter/h/kg (7%), and. h (5%), respectively. For clavulanic acid the parameters were.8 liter/kg (3%),.36 liter/kg (3%), 11 liters/h/kg (36%),.1 liters/h/kg (7%), and 1.95 h (%Yo), respectively. Our results suggest that the current dosing recommendations of 75 mg/kg every 1 h risk subtherapeutic clavulanic acid concentrations, and that 5 mg/kg every 6 h is a more rational dosing strategy. Bacterial infections are a common complication in the management of premature newborns in the intensive care nursery. Initial infections are often managed with ampicillin and gentamicin, while subsequent infections require antibiotics which cover gram-positive as well as gram-negative organisms. The antibiotics of choice in the Neonatal Intensive are Unit of The Women's Hospital of Greensboro have been vancomycin and ticarcillin-clavulanic acid. Unfortunately, few published data that can be used to describe the pharmacokinetics of ticarcillin and clavulanic acid in low-birth-weight premature neonates are available. Dosing guidelines in neonates are largely empiric and are founded on the pharmacokinetic data available for ticarcillin in newborns. urrent published guidelines recommend a ticarcillin dose of 75 mg/kg of body weight every 1 h until the infant is greater than weeks of postnatal age (13). The present study focused on obtaining pharmacokinetic parameters for both ticarcillin and clavulanic acid in small preterm neonates and developing dosing guidelines specifically for this patient population. MATERIALS AND METHODS The study was approved by the Institutional Review Board of the Moses H. one Memorial Hospital and the Women's Hospital of Greensboro, Greensboro, N.. Prior to enrollment of the patients, informed consent was obtained from the infants' parents or legal guardians. Neonates with documented or suspected sepsis were considered eligible for inclusion in the study if they were less than 36 weeks of gestational age as estimated on the basis of the method of Ballard et al. (3), weighed less than, g at birth, * orresponding author. Mailing address: Division of Neuropharmacology, Dent Neurologic Institute, Millard Fillmore Hospital, 3 Gates ircle, Buffalo, NY 19. Phone: (7) Fax: (7) and had received a course of at least 3 days of ampicillin and gentamicin for the treatment of sepsis. Prior courses of antibiotics were separated from the study treatment by a minimum of days. Eleven patients (seven males, four females) were enrolled in the study. Baseline chemistries, complete blood counts with differentials including platelets, and samples of blood and/or urine for culture were obtained. In addition, clinical evaluation, measurement of length and weight, and determination of gestational age were performed. Follow-up chemistries and complete blood counts with differentials including platelets were repeated daily while the infant was clinically acutely ill and at a minimum of twice weekly thereafter. Ticarcillin-clavulanic acid (lot 559; SmithKline Beecham Pharmaceuticals) was administered at a dose of 75 mg/kg over 15 min by using a syringe pump (model 11; Medfusion). The preparation administered was the commercially available product, which contains a 3-to-1 ratio of ticarcillin (7.5 mg/kg) to clavulanic acid (.5 mg/kg). Following administration, the intravenous access site was flushed with 1 ml of.9% Nal. Following infusion of the initial dose of ticarcillin-clavulanic acid ( h), blood samples were collected at.5, 1.5,, and 8 h from an umbilical artery catheter, when available, or from a capillary heel prick. Samples were immediately centrifuged for 1 min at > 1,75 rpm and the serum was harvested, placed in polypropylene vials, and frozen at -7 until analyzed by the Research and Development Laboratories of SmithKline Beecham Pharmaceuticals. Twelve courses of therapy were studied. Analysis of serum samples for ticarcillin and clavulanic acid concentrations was performed using a slightly modified version of the agar diffusion method described by Staniforth et al. (1). Ticarcillin concentrations in serum were determined by using Pseudomonas aeruginosa NT 171 as the test organism and antibiotic medium (Difco Laboratories). The assay was linear Downloaded from on November 1, 18 by guest
2 VOL. 38, 199 TIARILLIN-LAVULANI AID PHARMAOKINETIS 5 over the concentration range of 1.6 to 1 mg/liters. Withinday coefficients of variation (Vs) associated with the assay were 3.8 and 1.9% at the low and high ends of this concentration range, respectively. Between-day Vs were less than 1%. The lower detection limit for ticarcillin was 1.6 mg/liter. Analysis for clavulanic acid concentrations in serum was conducted by using Kiebsiella pneumoniae NT 118 as the test organism and nutrient agar (Oxoid). The assay was linear over the concentration range of.8 to 5 mg/liter. Within-day Vs associated with the low and high ends of the clavulanic acid concentration range were.7 and 1.3%, respectively. Between-day Vs were less than 1%. The lower detection limit was.78 mg/liter. Iterative two-stage analysis done with the computer software package Adapt II (6) was performed to fit candidate models to the serum concentration-time data. A description of this technique is provided elsewhere (11). Model discrimination was by Akaike's Information riterion (1). The serum concentration-time data reported by Fricke et al. (1) were initially fit by a linear, two-compartment open model to determine estimates of the maximum a posteriori (MAP)- Bayesian estimators for the volume of the central compartment, volume of the peripheral compartment, distributional clearance (Ld), and total clearance (L) for both ticarcillin and clavulanic acid. These results were then used as initial MAP-Bayesian estimators for the subsequent iterative twostage analysis of our data. Modeling incorporated a residual variance model, in which the standard deviations of the observations were linearly related to the fitted values. The parameters estimated for both ticarcillin and clavulanic acid included the volume of distribution in the central compartment (Vc), volume of distribution in the peripheral compartment (V) L, and Ld. The volume of distribution at steady state (V-{) and the terminal elimination half-life (t1l) were calculated on the basis of the following parameters: k = Ld/V, kpc = Ld/Vp, kel = L/Vc,B3= (kel + kcp + k S)/Y -/(kei+ k + kpc)/ - kel 1kpcg t1/ =.693/,B, and V%s = Vc + Vp, where kcp and kpc are intercompartmental rate constants and kel is the elimination rate constant, and 13 is the elimination rate constant. omparison of Vc, Vr, Ld, L, and t11 between ticarcillin and clavulanic acid was performed by Wilcoxin's rank sum test. Statistical significance was defined as a P value of <.5. TABLE 1. Subject demographics Subject Gestational Postnatal Postconceptional Wt (g) age (wk) age (days) age (wk) , , , ,659 6a b , , ,8 Median ,5 summary of the data for individual patients is provided in Table. Upon comparison of the pharmacokinetic parameters for clavulanic acid with those determined for ticarcillin, RESULTS Treatment was well tolerated by all subjects, with no significant adverse experiences or laboratory abnormalities being attributed to the administration of the ticarcillin-clavulanic acid combination. Subject demographics are summarized in Table 1. The pharmacokinetics of ticarcillin and clavulanic acid were best described by a linear, open two-compartment model. Figures 1A and A display the measured concentrations of ticarcillin and clavulanic acid in serum, respectively, following administration of the initial dose of tiarcillin-clavulanic acid. The area under the curve was variable, with a mean (range) of - 1,78 mg * h/kg/liter (559 to 3,57 mg h/kg/liter) for ticarcillin and 1 mg * h/kg/liter (6 to mg * h/kg/liter) for clavulanic acid. The median (interpatient V) for L, Ld, Vc, Vs, and t1, for ticarcillin were.7 liter/h/kg (7%),.1 liter/h/kg (7%),.3 liter/kg (1%),.6 liter/kg (8%), and. h (5%), respectively. For clavulanic acid, the parameters were as follows:.1 liter/h/kg (7%), 11 liter/h/kg (36%),.8 liter/kg (3%),.36 liter/kg (3%), and 1.95 h (%), respectively. A statistically significant differences were found. Larger V, (P <.5), L (P <.1), and Ld (P <.1) were found for clavulanic acid. The t11 of ticarcillin was approximately twofold longer (P <.1). No difference was found upon comparison of the ticarcillin V., with that of clavulanic acid (P >.5). Simulations of the ticarcillin and clavulanic acid concentrations at steady state were performed for the 1 individual treatment courses. The recommended dosage of 75 mg/kg every 1 h resulted in mean (range) peak and trough ticarcillin concentrations of 976 mg/liter (753 to 1,917 mg/liter) and mg/liter (.8 to 91 mg/liter), respectively (Fig. 1B). The concurrent peak and trough clavulanic acid concentrations were 6.8 mg/liter (.9 to 13 mg/liter) and.6 mg/liter (. to.9 mg/liter), respectively (Fig. B). This is in contrast to the mean (range) peak and trough concentrations on a regimen of 5 mg/kg every 6 h of 71 mg/liter (5 to 1,33 mg/liter) and 11 mg/liter (1.5 to 17 mg/liter) for ticarcillin (Fig. 1) and 5. mg/liter (.1 to 9.6 mg/liter) and.88 mg/liter (.57 to.6 mg/liter) for clavulanic acid (Fig. ). Use of a regimen of 75 mg/kg every 1 h would expose 1 of 1 (83%) subjects to serum ticarcillin concentrations below the upper limit of sensitivity, i.e., mg/liter. If the dosage of 5 mg/kg every 6 h is used, this is reduced to 3 of 1 (5%) subjects. lavulanic acid concentrations were less than mg/liter for a mean (range) of 65.5% (33 to 91.7%) of the dosing interval when the dosage of 75 mg/kg every 1 h was used, whereas they were less than mg/liter for 9.1% ( to 1%) of the dosing interval when the dosage of 5 mg/kg every 6 h was used. DISUSSION The sampling strategy used in our study was sparse and empiric. Retrospective analysis by optimal sampling theory (5, 6, 8) suggests that partitioning between V, and Vp as well as values of Ld are poorly identifiable for both ticarcillin and clavulanic acid. Vs, and L are well identified. The optimal four sampling times for this population are approximately,.75,, and 9 h following the completion of dose administration. In comparison with the optimal sampling times, the actual sampling times (.5, 1.5,, and 8 h following administration) provided larger theoretical Vs for partitioning between Vc and V and for values of Ld, but a similar information content on vafues of Vs. and L. Downloaded from on November 1, 18 by guest
3 6 BURSTEIN ET AL. ANTIMIROB. AGENTS HEMOTHER. A B 1 - c 1 ) -j 1I 1i 1 1I Time (hours) FIG. 1. Ticarcillin serum concentration-time profiles for individual subjects observed following administration of the initial 75-mg/kg Mae (A) and simulated for every 1-h dose of 75 mg/kg (B) and simulated for every 6-h dose of 5 mg of ticarcillin-clavulanic acid (Timentin) per kg. The horizontal lines represent the upper ( mg/liter) and lower ( mg/liter) limits for organism susceptibility to ticarcillin. The pharmacokinetic parameters that we determined were consistent with those reported by other investigators (9, 1) in infants closer to full term than ours,, Fayed et al. (9) reported a mean ± standard deviation t1, for ticarcillin of.5 ± 3. h and for clavulanic acid of ± 1.6 h. Their sample consisted of newborn infants with a mean gestational age of 3.7 weeks (range, 5 to 39 weeks) and a mean birth weight of 1,7 g (ranige, 895 to 3,9 g) (9). Fricke et al. (1), in their sample of seven preterm infants with a mean birth weight of,377 g (range, 1,915 to,65 g) and a mean gestational age of 35 weeks (range, 3 to 36 weeks), found a mean ± standard deviation Vs, and t1 for ticarcillin of.338 ±.35 liter/kg and. ±.5 h, respectively and for clavulanic acid of liter/kg and h, respectively. Additionally, the pharmacokinetics of ticarcillin and clavulanic acid were available for one patient with a gestational age of 3 weeks and a birth weight of 1, g. The Vss and t1l for ticarcillin were.515 liter/kg and h, respectively, and those for clavulanic acid were.1 liter/kg and.5 h, respectively, in that subject (1). Although it was not surprising, the more rapid clearance of clavulanic acid in comparison with that of ticarcillin is of concern. Ticarcillin, with its primarily renal route of elimination, would be expected to exhibit diminished clearance in this population, which possesses relatively immature kidneys and tubular secretory capacity (). In contrast, clavulanic acid is eliminated primarily through nonrenal mechanisms (7), with these mechanisms generally being more mature than renal 1 1' function in this population. The more rapid clearance and shorter t11 of clavulanic acid potentially leave ticarcillin susceptible to destruction by,-lactamase during that portion of the dosing interval when.clavulanic acid concentrations are negligible. This concern arises in cases in which ticarcillinclavulanic acid-susceptible, ticarcillin-resistant organisms are suspected and/or isolated. As a result of the different clearances of ticarcillin and clavulanic acid, questions arise as to the appropriate method for dosing ticarcillin-clavulanic acid in this population. Of particular interest is the issue of the appropriate target concentrations of clavulanic acid necessary for the adequate inhibition of 1-lactamase. To determine this optimal concentration, a knowledge of the turnover number, or the number of clavulanic acid molecules required to inactivate a single,-lactamase molecule, is required for each type of,-lactamase that may be clinically encountered. Bush et al. (), in thbir evaluation of the kinetic interaction of tazobactam with,b-lactamases, additionally determined the number of turnovers required for inactivation of numerous,-lactamase enzymes in the presence of clavulanic acid. This value varies among the different enzymes, ranging from a value of 1 for P1 enzymes to >5, for P99 and ra enzymes. Alterations in the amino acid profiles of the different 1-lactamase enzymes are considered to be responsible for the variability in turnover numbers. The investigators concluded, on the basis of the tazobactam data, that the enzymes tested demonstrated reversible reactions upon incubation with ta- Downloaded from on November 1, 18 by guest
4 VOL. 38, 199 TIARILLIN-LAVULANI AID PHARMAOKINETIS 7 1 A 1 B 1 E a a) c Time (hours) FIG.. lavulanic acid serum concentration-time profiles for individual subjects observed following administration of the initial 75-mg/kg dose (A) and simulated for every 1-h dose of 75 mg/kg and simulated for every 6-h dose of 5 mg of ticarcillin-clavulanic acid (Timentin) per kg. The horizontal line represents the minimum therapeutic concentration of clavulanic acid ( mg/liter). zobactam. The degree of reversibility of inhibition was related to the turnover number for tazobactam relative to the individual enzymes. Because this value varied across enzymes, the investigators concluded that successful inhibition of all,b-lactamases requires the presence of a minimum maintained concentration of tazobactam. While the investigators described above failed to extend their conclusion to clavulanic acid, a previous investigation (1) supports the extrapolation of this conclusion. Those investigators found that incubation of various concentrations of clavulanic acid with,-lactamase from an Escherichia coli TABLE. Ticarcillin and clavulanic acid pharmacokinetics Ticarcillin RTEM strain resulted in various degrees of enzyme inhibition. As the ratio of clavulanic acid to enzyme was increased there was a concomitant increase in the extent of irreversible inhibition of the P-lactamase enzyme. However, at all but the highest ratio of inhibitor to enzyme (15:1) a variable recovery of enzyme activity was demonstrated. At a molar ratio of 15, complete inhibition was observed. Recovery of enzyme activity appeared to begin upon complete utilization of the available clavulanic acid. It may be hypothesized that, similar to the conclusions for tazobactam (), maintenance of a minimum concentration of clavulanic acid is warranted. lavulanic acid Subject V V. Ld L t/ V. V. Ld L t1/ (liter/kg) (liter/kg) (liter/h/kg) (liter/h/kg) (h) (liter/kg) (liter/kg) (liter/h/kg) (liter/h/kg) (h) a b Median Minimum Maximum Downloaded from on November 1, 18 by guest
5 8 BURSTEIN ET AL. ANTIMIROB. AGENTS HEMOTHER. One proposed dosing strategy is such that in vivo concentrations are maintained above a certain finite concentration throughout the entire dosing interval. This value has generally been considered to be mg/liter because typical measures of MIs for organisms use a fixed -mg/liter concentration of clavulanic acid (15). In the presence of a fixed -mg/liter concentration of clavulanic acid, P-lactamase-producing strains of Staphylococcus aureus, Staphylococcus epidermidis, Branhamella catarrhalis, Haemophilus influenzae, Neisseria gonorrhoeae, E. coli, Kiebsiella species, and Bacteroides species exhibit increased susceptibilities to ticarcillin in comparison with their susceptibilities when they are exposed to ticarcillin alone (15). Since the need for persistent concentrations of clavulanic acid cannot be excluded, we believe a more conservative dosing strategy, maintaining a clavulanic acid concentration of greater than mg/liter, is the most effective approach, provided that excessive concentrations of ticarcillin in serum can be avoided. The main toxicity of ticarcillin appears to be inhibition of platelet adhesion when ticarcillin is present at levels of approximately 1, mg/liter. No clear reason for concern for concentrations less than this is apparent, although platelet adhesion may theoretically be inhibited at lower concentrations in premature infants. Following administration of the initial dose studied, the majority of our subjects exhibited clavulanic acid concentrations of less than mg/liter prior to the 8-h sampling time. At the extreme, two subjects exhibited concentrations of clavulanic acid of less than mg/liter as early as 1.5 to h following administration of the single dose. These low concentrations would continue to be a problem at steady state. Using the pharmacokinetic parameters determined for our individual subjects, we have simulated various dosing regimens, predicting the expected concentration-time data. Simulations were performed by assuming that the ratio of ticarcillin to clavulanic acid administered could not be modified. On the basis of those simulations, we suggest a dosage of 5 mg of ticarcillin-clavulanic acid per kg administered every 6 h. Figures 1 and display the simulated steady-state profiles of concentrations in serum for ticarcillin and clavulanic acid associated with this regimen. While providing an additional 5 mg of ticarcillin-clavulanic acid per kg daily, with the resultant increases in the areas under the curve for ticarcillin and clavulanic acid, maximal concentrations would be expected to be less than those provided with 75 mg/kg dosed every 1 h. While this regimen leaves a number of individuals with subtherapeutic concentrations of clavulanic acid, it provides therapeutic concentrations for a greater percentage of the dosing interval. Use of the doses of ticarcillin-clavulanic acid that were predicted to provide therapeutic steady-state concentrations of clavulanic acid throughout the entire dosing interval runs the risk of providing excessive, and potentially toxic, maximal concentrations of ticarcillin. The pharmacokinetics of ticarcillin and clavulanic acid after administration to our subjects were similar to those after administration to older, more mature infants in earlier studies (9, 1). Because of the finding of significantly larger clearances and shorter t1/ values of clavulanic acid in comparison with those of ticarcillin, there is a risk that the concentrations of clavulanic acid may become subtherapeutic, thereby warranting revision of current dosing practices. On the basis of the pharmacokinetics of these agents in our small number of subjects, an alternative dosing recommendation on the basis of the assumption that a minimum concentration of clavulanic acid of,ug/ml will provide a favorable turnover number is the administration of 5 mg of ticarcillin-clavulanic acid per kg every 6 h. Further studies are necessary to validate prospectively the adequacy of this regimen, assess the clinical impact, and develop criteria to more adequately optimize dosing regimens. AKNOWLEDGMENT The assistance of SmithKline Beecham Pharmaceuticals in the determination of ticarcillin and clavulanic acid concentrations is acknowledged. REFERENES 1. Akaike, H An information criterion (AI). Math Sci. 1:5-9.. Assael, B. M Pharmacokinetics and drug distribution during post natal development. Pharmacol. Ther. 18: Ballard, J. L, K. K. Novak, and M. Driver A simplified score for assessment of fetal maturation of newly born infants. J. Pediatr. 95(5 pt 1): Bush, K.,. Macalintal, B. A. Rasmussen, V. J. Lee, and Y. Yang Kinetic interactions of tazobactam with,b-lactamases for all major structural classes. Antimicrob. Agents hemother. 37: D'Argenio, D. Z Optimal sampling times for pharmacokinetic experiments. J. Pharmacokinet. 9: D'Argenio, D. Z., and A. Schumitzky Adapt II users guide. Biomedical simulations resource. University of Southern alifornia, Los Angeles. 7. Davies, B. E., P. E. oates, J. G. H. larke, A. R. Thawley, and J. A. Sutton Bioavailability and pharmacokinetics of clavulanic acid in healthy subjects. Int. J. lin. Pharmacol. Ther. Toxicol. 3: Drusano, G. L, A. Forrest, M. J. Snyder, M. D. Reed, and J. L. Blumer An evaluation of optimal sampling strategy and adaptive study design. lin. Pharmacol. Ther. : Fayed, S. B., A. M. Sutton, T. L Turner, and T. A. McAllister The prophylactic use of ticarcillin/clavulanate in the neonate. J. Antimicrob. hemother. 19: Fisher, J., R. L. harnas, and J. R Knowles Kinetic studies on the inactivation of Escherichia coli RTEM f3-lactmase by clavulanic acid. Biochemistry 17: Forrest, A.,. H. Ballow, D. E. Nix, M.. Birmingham, and J. J. Schentag Development of a population pharmacokinetic model and optimal sampling strategies for intravenous ciprofloxacin. Antimicrob. Agents hemother. 37: Fricke, G., M. Doerek, D. Hafner, R. Horton, and M. Kresken The pharmacokinetics of ticarcillin/clavulanate acid in neonates. J. Antimicrob. hemother. (Suppl. B): Prober,. G., D. K. Stevenson, and W. E. Benitz The use of antibiotics in neonates weighing less than 1 grams. Pediatr. Infect. Dis. J. 9: Staniforth, D. M., P. E. oates, B. E. Davies, and R Horton Pharmacokinetic of parenteral ticarcillin formulated with clavulanic acid: timentin. Int. J. lin. Pharmacol. Ther. Toxicol. : Sutherland, R, A. S. Beale, R J. Boon, K. E. Griflin, B. Slocombe, D. H. Stokes, and A. RK White Antibacterial activity of ticarcillin in the presence of clavulanate potassium. Am. J. Med. 79(Suppl. 5B):13-. Downloaded from on November 1, 18 by guest
Pharmacokinetics of amoxycillin and clavulanic acid in
Br. J. clin. Pharmac. (1988), 26, 385-390 Pharmacokinetics of amoxycillin and clavulanic acid in haemodialysis patients following intravenous administration of Augmentin B. E. DAVIES', R. BOON2, R. HORTON2,
More informationPharmacological Evaluation of Amikacin in Neonates
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, JUlY 1975, p. 86-90 Copyright 0 1975 American Society for Microbiology Vol. 8, No. 1 Printed in U.SA. Pharmacological Evaluation of Amikacin in Neonates JORGE B.
More informationProtein Synthesis Inhibitors
Protein Synthesis Inhibitors Assistant Professor Dr. Naza M. Ali 11 Nov 2018 Lec 7 Aminoglycosides Are structurally related two amino sugars attached by glycosidic linkages. They are bactericidal Inhibitors
More informationChildrens Hospital Antibiogram for 2012 (Based on data from 2011)
Childrens Hospital Antibiogram for 2012 (Based on data from 2011) Prepared by: Department of Clinical Microbiology, Health Sciences Centre For further information contact: Andrew Walkty, MD, FRCPC Medical
More informationCurricular Components for Infectious Diseases EPA
Curricular Components for Infectious Diseases EPA 1. EPA Title Promoting antimicrobial stewardship based on microbiological principles 2. Description of the A key role for subspecialists is to utilize
More informationIntroduction to Pharmacokinetics and Pharmacodynamics
Introduction to Pharmacokinetics and Pharmacodynamics Diane M. Cappelletty, Pharm.D. Assistant Professor of Pharmacy Practice Wayne State University August, 2001 Vocabulary Clearance Renal elimination:
More informationSZENT ISTVÁN UNIVERSITY. Doctoral School of Veterinary Science
SZENT ISTVÁN UNIVERSITY Doctoral School of Veterinary Science Comparative pharmacokinetics of the amoxicillinclavulanic acid combination in broiler chickens and turkeys, susceptibility and stability tests
More informationThese recommendations were approved for use by the Pharmaceutical and Therapeutics Committee, RCWMCH on 1 February 2017.
Antibiotic regimens for suspected hospital-acquired infection (HAI) outside the Paediatric Intensive Care Unit at Red Cross War Memorial Children s Hospital (RCWMCH) Lead author: Brian Eley Contributing
More informationOPTIMIZATION OF PK/PD OF ANTIBIOTICS FOR RESISTANT GRAM-NEGATIVE ORGANISMS
HTIDE CONFERENCE 2018 OPTIMIZATION OF PK/PD OF ANTIBIOTICS FOR RESISTANT GRAM-NEGATIVE ORGANISMS FEDERICO PEA INSTITUTE OF CLINICAL PHARMACOLOGY DEPARTMENT OF MEDICINE, UNIVERSITY OF UDINE, ITALY SANTA
More informationPharmacokinetic & Pharmadynamic of Once Daily Aminoglycosides (ODA) and their Monitoring. Janis Chan Pharmacist, UCH 2008
Pharmacokinetic & Pharmadynamic of Once Daily Aminoglycosides (ODA) and their Monitoring Janis Chan Pharmacist, UCH 25-4-2008 2008 Aminoglycosides (AG) 1. Gentamicin 2. Amikacin 3. Streptomycin 4. Neomycin
More informationThey are updated regularly as new NICE guidance is published. To view the latest version of this NICE Pathway see:
Antibiotic treatment and monitoring for suspected or confirmed early-onset neonatal infection bring together everything NICE says on a topic in an interactive flowchart. are interactive and designed to
More informationScottish Medicines Consortium
Scottish Medicines Consortium tigecycline 50mg vial of powder for intravenous infusion (Tygacil ) (277/06) Wyeth 9 June 2006 The Scottish Medicines Consortium (SMC) has completed its assessment of the
More informationOriginal Research Article
Study of Preterm Infants with Different Gestational Age: Modifying Amikacin Sulphate Dosage Regimen 1 1,2 Bindiya Chauhan, Sunil S Jalalpure Dr. Prabhakar Kore Basic Science Research Center, KLE Academy
More informationPatients. Excludes paediatrics, neonates.
Full title of guideline Author Division & Speciality Scope Gentamicin Prescribing Guideline For Adult Patients Annette Clarkson, Specialist Clinical Pharmacist Antimicrobials and Infection Control All
More informationCOMMITTEE FOR VETERINARY MEDICINAL PRODUCTS
The European Agency for the Evaluation of Medicinal Products Veterinary Medicines and Information Technology EMEA/MRL/728/00-FINAL April 2000 COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS STREPTOMYCIN AND
More informationInternational Journal of Advances in Pharmacy and Biotechnology Vol.3, Issue-2, 2017, 1-7 Research Article Open Access.
I J A P B International Journal of Advances in Pharmacy and Biotechnology Vol.3, Issue-2, 2017, 1-7 Research Article Open Access. ISSN: 2454-8375 COMPARISON OF ANTIMICROBIAL ACTIVITY AND MIC OF BRANDED
More informationBurton's Microbiology for the Health Sciences. Chapter 9. Controlling Microbial Growth in Vivo Using Antimicrobial Agents
Burton's Microbiology for the Health Sciences Chapter 9. Controlling Microbial Growth in Vivo Using Antimicrobial Agents Chapter 9 Outline Introduction Characteristics of an Ideal Antimicrobial Agent How
More informationClinical Policy: Linezolid (Zyvox) Reference Number: CP.PMN.27 Effective Date: Last Review Date: Line of Business: HIM*, Medicaid
Clinical Policy: (Zyvox) Reference Number: CP.PMN.27 Effective Date: 09.01.06 Last Review Date: 02.19 Line of Business: HIM*, Medicaid Coding Implications Revision Log See Important Reminder at the end
More informationPercent Time Above MIC ( T MIC)
8 2007 Percent Time Above MIC ( T MIC) 18 8 25 18 12 18 MIC 1 1 T MIC 1 500 mg, 1 2 (500 mg 2) T MIC: 30 (TA30 ) 71.9 59.3 T MIC: 50 (TA50 ) 21.5, 0.1 1,000 mg 2 TA30 80.5, 68.7 TA50 53.2, 2.7 500 mg 3
More informationAppropriate antimicrobial therapy in HAP: What does this mean?
Appropriate antimicrobial therapy in HAP: What does this mean? Jaehee Lee, M.D. Kyungpook National University Hospital, Korea KNUH since 1907 Presentation outline Empiric antimicrobial choice: right spectrum,
More informationApproach to pediatric Antibiotics
Approach to pediatric Antibiotics Gassem Gohal FAAP FRCPC Assistant professor of Pediatrics objectives To be familiar with common pediatric antibiotics o Classification o Action o Adverse effect To discus
More informationCOMMITTEE FOR MEDICINAL PRODUCTS FOR VETERINARY USE
European Medicines Agency Veterinary Medicines and Inspections EMEA/CVMP/211249/2005-FINAL July 2005 COMMITTEE FOR MEDICINAL PRODUCTS FOR VETERINARY USE DIHYDROSTREPTOMYCIN (Extrapolation to all ruminants)
More informationScottish Medicines Consortium
Scottish Medicines Consortium daptomycin 350mg powder for concentrate for solution for infusion (Cubicin ) Chiron Corporation Limited No. (248/06) 10 March 2006 The Scottish Medicines Consortium (SMC)
More informationKeywords: amoxicillin/clavulanate, respiratory tract infection, antimicrobial resistance, pharmacokinetics/pharmacodynamics, appropriate prescribing
Journal of Antimicrobial Chemotherapy (2004) 53, Suppl. S1, i3 i20 DOI: 10.1093/jac/dkh050 Augmentin (amoxicillin/clavulanate) in the treatment of community-acquired respiratory tract infection: a review
More informationJerome J Schentag, Pharm D
Clinical Pharmacy and Optimization of Antibiotic Usage: How to Use what you have Learned in Pharmacokinetics and Pharmacodynamics of Antibiotics Jerome J Schentag, Pharm D Presented at UCL on Thursday
More informationUSA Product Label CLINTABS TABLETS. Virbac. brand of clindamycin hydrochloride tablets. ANADA # , Approved by FDA DESCRIPTION
VIRBAC CORPORATION USA Product Label http://www.vetdepot.com P.O. BOX 162059, FORT WORTH, TX, 76161 Telephone: 817-831-5030 Order Desk: 800-338-3659 Fax: 817-831-8327 Website: www.virbacvet.com CLINTABS
More informationCOMMITTEE FOR VETERINARY MEDICINAL PRODUCTS
The European Agency for the Evaluation of Medicinal Products Veterinary Medicines and Inspections EMEA/CVMP/627/01-FINAL COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS GUIDELINE FOR THE DEMONSTRATION OF EFFICACY
More informationAntimicrobial Pharmacodynamics
Antimicrobial Pharmacodynamics November 28, 2007 George P. Allen, Pharm.D. Assistant Professor, Pharmacy Practice OSU College of Pharmacy at OHSU Objectives Become familiar with PD parameters what they
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Enrocare 50 mg/ml Solution for Injection for Cattle, Pigs, Dogs and Cats (UK, IE, FR) Floxadil 50 mg/ml Solution for Injection
More informationPharmacology Week 6 ANTIMICROBIAL AGENTS
Pharmacology Week 6 ANTIMICROBIAL AGENTS Mechanisms of antimicrobial action Mechanisms of antimicrobial action Bacteriostatic - Slow or stop bacterial growth, needs an immune system to finish off the microbe
More informationMARBOCYL 10% SUMMARY OF PRODUCT CHARACTERISTICS
MARBOCYL 10% SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT MARBOCYL 10%, solution for injection for cattle and swine 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Marbofloxacin...100.0
More informationEXCEDE Sterile Suspension
VIAL LABEL MAIN PANEL PRESCRIPTION ANIMAL REMEDY KEEP OUT OF REACH OF CHILDREN READ SAFETY DIRECTIONS FOR ANIMAL TREATMENT ONLY EXCEDE Sterile Suspension 200 mg/ml CEFTIOFUR as Ceftiofur Crystalline Free
More informationSUMMARY OF PRODUCT CHARACTERISTICS. Enrotron 50 mg/ml Solution for injection for cattle, pigs, dogs and cats
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Enrotron 50 mg/ml Solution for injection for cattle, pigs, dogs and cats 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each
More informationTreatment of Respiratory Tract Infections Prof. Mohammad Alhumayyd Dr. Aliah Alshanwani
Treatment of Respiratory Tract Infections Prof. Mohammad Alhumayyd Dr. Aliah Alshanwani 30-1-2018 1 Objectives of the lecture At the end of lecture, the students should be able to understand the following:
More informationDETERMINING CORRECT DOSING REGIMENS OF ANTIBIOTICS BASED ON THE THEIR BACTERICIDAL ACTIVITY*
44 DETERMINING CORRECT DOSING REGIMENS OF ANTIBIOTICS BASED ON THE THEIR BACTERICIDAL ACTIVITY* AUTHOR: Cecilia C. Maramba-Lazarte, MD, MScID University of the Philippines College of Medicine-Philippine
More informationOther Beta - lactam Antibiotics
Other Beta - lactam Antibiotics Assistant Professor Dr. Naza M. Ali Lec 5 8 Nov 2017 Lecture outlines Other beta lactam antibiotics Other inhibitors of cell wall synthesis Other beta-lactam Antibiotics
More informationEuropean Public MRL assessment report (EPMAR)
18 March 2016 EMA/CVMP/619817/2015 Committee for Medicinal Products for Veterinary Use European Public MRL assessment report (EPMAR) Gentamicin (all mammalian food producing species and fin fish) On 3
More informationVOL. XXIII NO. II THE JOURNAL OF ANTIBIOTICS 559. ANTIBIOTIC 6640.* Ill
VOL. XXIII NO. II THE JOURNAL OF ANTIBIOTICS 559 ANTIBIOTIC 6640.* Ill BIOLOGICAL STUDIES WITH ANTIBIOTIC 6640, A NEW BROAD-SPECTRUM AMINOGLYCOSIDE ANTIBIOTIC J. Allan Waitz, Eugene L. Moss, Jr., Edwin
More information11/10/2016. Skin and Soft Tissue Infections. Disclosures. Educational Need/Practice Gap. Objectives. Case #1
Disclosures Selecting Antimicrobials for Common Infections in Children FMR-Contemporary Pediatrics 11/2016 Sean McTigue, MD Assistant Professor of Pediatrics, Pediatric Infectious Diseases Medical Director
More informationCell Wall Inhibitors. Assistant Professor Naza M. Ali. Lec 3 7 Nov 2017
Cell Wall Inhibitors Assistant Professor Naza M. Ali Lec 3 7 Nov 2017 Cell wall The cell wall is a rigid outer layer, it completely surrounds the cytoplasmic membrane, maintaining the shape of the cell
More informationDOSAGE FORMS AND STRENGTHS Otic Suspension: Each OTIPRIO vial contains 1 ml of 6% (60 mg/ml) ciprofloxacin otic suspension. (3)
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use OTIPRIO safely and effectively. See full prescribing information for OTIPRIO. OTIPRIO (ciprofloxacin
More informationEffective 9/25/2018. Contact for previous versions.
Pharmacokinetic and Pharmacodynamic Dose Optimization of Antibiotics (β-lactams, aminoglycosides, and ciprofloxacin) for the Treatment of Gram-Negative Infections Adult Inpatient/Emergency Department Clinical
More informationBacterial Resistance of Respiratory Pathogens. John C. Rotschafer, Pharm.D. University of Minnesota
Bacterial Resistance of Respiratory Pathogens John C. Rotschafer, Pharm.D. University of Minnesota Antibiotic Misuse ~150 million courses of antibiotic prescribed by office based prescribers Estimated
More informationAntimicrobial Stewardship Strategy: Dose optimization
Antimicrobial Stewardship Strategy: Dose optimization Review and individualization of antimicrobial dosing based on the characteristics of the patient, drug, and infection. Description This is an overview
More informationDETERMINANTS OF TARGET NON- ATTAINMENT IN CRITICALLY ILL PATIENTS RECEIVING β-lactams
DETERMINANTS OF TARGET NON- ATTAINMENT IN CRITICALLY ILL PATIENTS RECEIVING β-lactams Jan J. De Waele MD PhD Surgical ICU Ghent University Hospital Ghent, Belgium Disclosures Financial: consultancy for
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Kelacyl 100 mg/ml, solution for injection for cattle and pigs (BG, CY, CZ, DE, EL, FR, HU, IE, IT, LT, PL, PT, RO, SK, UK)
More informationNew Method for Antibiotic Susceptibility Testing
ANTIMIROBIAL AGENTS AND HEMOTHERAPY, Aug. 1972, p. 51-56 opyright 1972 American Society for Microbiology Vol. 2, No. 2 Printed in U.S.A. New Method for Antibiotic Susceptibility Testing G. N. ROLINSON
More informationSpeciality: Therapeutics
Gentamicin Title of Guideline (must include the word Guideline (not protocol, policy, procedure etc) Contact Name and Job Title (author) Directorate & Speciality Date of submission May 2017 Date on which
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Marbocare 20 mg/ml solution for injection for cattle and pigs (UK, IE, FR) Odimar 20 mg/ml solution for injection for cattle
More informationLe infezioni di cute e tessuti molli
Le infezioni di cute e tessuti molli SCELTE e STRATEGIE TERAPEUTICHE Pierluigi Viale Clinica di Malattie Infettive Policlinico S. Orsola Malpighi Treatment of complicated skin and skin structure infections
More informationAntibiotic Stewardship Program (ASP) CHRISTUS SETX
Antibiotic Stewardship Program (ASP) CHRISTUS SETX Program Goals I. Judicious use of antibiotics Decrease use of broad spectrum antibiotics and deescalate use based on clinical symptoms Therapeutic duplication:
More informationAcute Pyelonephritis POAC Guideline
Acute Pyelonephritis POAC Guideline Refer full regional pathway http://aucklandregion.healthpathways.org.nz/33444 EXCLUSION CRITERIA: COMPLICATED PYELONEPHRITIS Discuss with relevant specialist for advice
More informationConsiderations in antimicrobial prescribing Perspective: drug resistance
Considerations in antimicrobial prescribing Perspective: drug resistance Hasan MM When one compares the challenges clinicians faced a decade ago in prescribing antimicrobial agents with those of today,
More informationAppropriate Antimicrobial Therapy for Treatment of
Appropriate Antimicrobial Therapy for Treatment of Staphylococcus aureus infections ( MRSA ) By : A. Bojdi MD Assistant Professor Inf. Dis. Dep. Imam Reza Hosp. MUMS Antibiotics Still Miracle Drugs Paul
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Amfipen LA 100 mg/ml suspension for injection 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Active substance: Each ml contains:
More informationAntibiotic. Antibiotic Classes, Spectrum of Activity & Antibiotic Reporting
Antibiotic Antibiotic Classes, Spectrum of Activity & Antibiotic Reporting Any substance of natural, synthetic or semisynthetic origin which at low concentrations kills or inhibits the growth of bacteria
More informationMetacam 1.5 mg/ml oral suspension for dogs
Metacam 1.5 mg/ml oral suspension for dogs Species:Dogs Therapeutic indication:pharmaceuticals: Neurological preparations: Analgesics, Other NSAIDs, Locomotor (including navicular and osteoarthritis) Active
More informationClinical Practice Standard
Clinical Practice Standard 1-20-6-1-010 TITLE: INTRAVENOUS TO ORAL CONVERSION FOR ANTIMICROBIALS A printed copy of this document may not reflect the current, electronic version on OurNH. APPLICABILITY:
More informationProphylactic antibiotic timing and dosage. Dr. Sanjeev Singh AIMS, Kochi
Prophylactic antibiotic timing and dosage Dr. Sanjeev Singh AIMS, Kochi Meaning - Webster Medical Definition of prophylaxis plural pro phy lax es \-ˈlak-ˌsēz\play : measures designed to preserve health
More informationZOETIS INC. 333 PORTAGE STREET, KALAMAZOO, MI, Telephone: Customer Service: Website: EXCEDE FOR SWINE
ZOETIS INC. 333 PORTAGE STREET, KALAMAZOO, MI, 49007 Telephone: 269-359-4414 Customer Service: 888-963-8471 Website: www.zoetis.com Every effort has been made to ensure the accuracy of the information
More informationWhat s new in EUCAST methods?
What s new in EUCAST methods? Derek Brown EUCAST Scientific Secretary Interactive question 1 MIC determination MH-F broth for broth microdilution testing of fastidious microorganisms Gradient MIC tests
More informationJournal of Antimicrobial Chemotherapy Advance Access published August 26, 2006
Journal of Antimicrobial Chemotherapy Advance Access published August, Journal of Antimicrobial Chemotherapy doi:./jac/dkl Pharmacodynamics of moxifloxacin and levofloxacin against Streptococcus pneumoniae,
More information4/3/2017 CLINICAL PEARLS: UPDATES IN THE MANAGEMENT OF NOSOCOMIAL PNEUMONIA DISCLOSURE LEARNING OBJECTIVES
CLINICAL PEARLS: UPDATES IN THE MANAGEMENT OF NOSOCOMIAL PNEUMONIA BILLIE BARTEL, PHARMD, BCCCP APRIL 7 TH, 2017 DISCLOSURE I have had no financial relationship over the past 12 months with any commercial
More informationIndicated for the treatment of pruritus associated with allergic dermatitis and the clinical manifestations of atopic dermatitis in dogs.
Zoetis UK Limited Telephone: 0845 300 8034 Website: www.zoetis.co.uk Email: customersupportuk@zoetis.com Apoquel film-coated for dogs Species: Therapeutic indication: Active ingredient: Product: Product
More informationPharmacokinetics of Amoxicillin/Clavulanic Acid Combination after Oral Administration of New Suspension Formulations in Human Volunteers
R Iranian Journal of Pharmaceutical Sciences Summer 2006: 2(3): 129-136 www.ijps.ir Original Article Pharmacokinetics of Amoxicillin/Clavulanic Acid Combination after Oral Administration of New Suspension
More informationمادة االدوية المرحلة الثالثة م. غدير حاتم محمد
م. مادة االدوية المرحلة الثالثة م. غدير حاتم محمد 2017-2016 ANTIMICROBIAL DRUGS Antimicrobial drugs Lecture 2 The Action of Antimicrobial Drugs 1- Inhibitors of bacterial Cell Wall Synthesis. β-lactams(
More informationMICRONAUT MICRONAUT-S Detection of Resistance Mechanisms. Innovation with Integrity BMD MIC
MICRONAUT Detection of Resistance Mechanisms Innovation with Integrity BMD MIC Automated and Customized Susceptibility Testing For detection of resistance mechanisms and specific resistances of clinical
More informationANTIBIOTIC PRESCRIBING POLICY FOR DIABETIC FOOT DISEASE IN SECONDARY CARE
ANTIBIOTIC PRESCRIBING POLICY FOR DIABETIC FOOT DISEASE IN SECONDARY CARE Version 1.0 Date ratified June 2009 Review date June 2011 Ratified by Authors Consultation Nottingham Antibiotic Guidelines Committee
More informationCHAPTER:1 THE RATIONAL USE OF ANTIBIOTICS. BY Mrs. K.SHAILAJA., M. PHARM., LECTURER DEPT OF PHARMACY PRACTICE, SRM COLLEGE OF PHARMACY
CHAPTER:1 THE RATIONAL USE OF ANTIBIOTICS BY Mrs. K.SHAILAJA., M. PHARM., LECTURER DEPT OF PHARMACY PRACTICE, SRM COLLEGE OF PHARMACY Antibiotics One of the most commonly used group of drugs In USA 23
More informationAlasdair P. MacGowan*, Mandy Wootton and H. Alan Holt
Journal of Antimicrobial Chemotherapy (1999) 43, 345 349 JAC The antibacterial efficacy of levofloxacin and ciprofloxacin against Pseudomonas aeruginosa assessed by combining antibiotic exposure and bacterial
More informationFACTORS AFFECTING THE POST-DIALYSIS LEVELS OF VANCOMYCIN AND GENTAMICIN IN HAEMODIALYSIS PATIENTS. Acute-Haemodialysis Team St.
FACTORS AFFECTING THE POST-DIALYSIS LEVELS OF VANCOMYCIN AND GENTAMICIN IN HAEMODIALYSIS PATIENTS. Acute-Haemodialysis Team St. Helier s Hospital Vancomycin and Gentamicin Audit Renal Unit St Helier Hospital
More informationCell Wall Weakeners. Antimicrobials: Drugs that Weaken the Cell Wall. Bacterial Cell Wall. Bacterial Resistance to PCNs. PCN Classification
Cell Wall Weakeners Antimicrobials: Drugs that Weaken the Cell Wall Beta Lactams Penicillins Cephalosporins Carbapenems Aztreonam Vancomycin Teicoplanin Bacterial Cell Wall Bacterial cytoplasm is hypertonic
More informationCanadian Nosocomial Infection Surveillance Program 2018 SURVEILLANCE FOR HEALTHCARE ACQUIRED CEREBROSPINAL FLUID SHUNT ASSOCIATED INFECTIONS
Canadian Nosocomial Infection Surveillance Program 2018 SURVEILLANCE FOR HEALTHCARE ACQUIRED CEREBROSPINAL FLUID SHUNT ASSOCIATED INFECTIONS FINAL November 29, 2017 Working Group: Joanne Langley (Chair),
More informationRoutine internal quality control as recommended by EUCAST Version 3.1, valid from
Routine internal quality control as recommended by EUCAST Version.1, valid from 01-01-01 Escherichia coli Pseudomonas aeruginosa Staphylococcus aureus Enterococcus faecalis Streptococcus pneumoniae Haemophilus
More informationPharmacokinetics of the Bovine Formulation of Enrofloxacin (Baytril 100) in Horses
C. Boeckh, C. Buchanan, A. Boeckh, S. Wilkie, C. Davis, T. Buchanan, and D. Boothe Pharmacokinetics of the Bovine Formulation of Enrofloxacin (Baytril 100) in Horses Christine Boeckh, DVM, MS a Charles
More informationOBSTETRICS & GYNAECOLOGY. Penicillin G 5 million units IV ; followed by 2.5 million units 4hourly upto delivery
OBSTETRICS & GYNAECOLOGY A.OBSTETRICS Infection/Condition/likely organism Intrapartum Group B Streptococcal (GBS) infection; positive mothers Suggested treatment Preferred Penicillin G 5 million units
More informationStanding Orders for the Treatment of Outpatient Peritonitis
Standing Orders for the Treatment of Outpatient Peritonitis 1. Definition of Peritonitis: a. Cloudy effluent. b. WBC > 100 cells/mm3 with >50% polymorphonuclear (PMN) cells with minimum 2 hour dwell. c.
More informationCombination vs Monotherapy for Gram Negative Septic Shock
Combination vs Monotherapy for Gram Negative Septic Shock Critical Care Canada Forum November 8, 2018 Michael Klompas MD, MPH, FIDSA, FSHEA Professor, Harvard Medical School Hospital Epidemiologist, Brigham
More informationQ1. (a) Clostridium difficile is a bacterium that is present in the gut of up to 3% of healthy adults and 66% of healthy infants.
Q1. (a) Clostridium difficile is a bacterium that is present in the gut of up to 3% of healthy adults and 66% of healthy infants. C. difficile rarely causes problems, either in healthy adults or in infants.
More informationMARBOCYL FD SUMMARY OF PRODUCT CHARACTERISTICS
MARBOCYL FD SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT MARBOCYL FD 1 %, powder and solvent for solution for injection, for cats and dogs. 2. QUALITATIVE AND QUANTITATIVE
More information1 TRADE NAME OF THE MEDICINAL PRODUCT. Gentamicin Paediatric 20mg/2ml Solution for Injection 2 QUALITATIVE AND QUANTITATIVE COMPOSITION
1 TRADE NAME OF THE MEDICINAL PRODUCT Gentamicin Paediatric 20mg/2ml Solution for Injection 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each 2ml contains 20mg of Gentamicin as Gentamicin Sulfate Excipient
More informationJust where it s needed.
Relief. Just where it s needed. Tissue-selective 7,8 Strong safety profile 5,6,10,11 For dogs and cats Onsior is available in a range of convenient and easy-to-dose formulations. Injectable solution for
More information2. Albany College of Pharmacy and Health Sciences, Albany, NY, USA
AAC Accepted Manuscript Posted Online 17 August 2015 Antimicrob. Agents Chemother. doi:10.1128/aac.01032-15 Copyright 2015, American Society for Microbiology. All Rights Reserved. 1 Optimizing the Initial
More informationPRACTIC GUIDELINES for APPROPRIATE ANTIBIOTICS USE
PRACTIC GUIDELINES for APPROPRIATE ANTIBIOTICS USE Global Alliance for Infection in Surgery World Society of Emergency Surgery (WSES) and not only!! Aims - 1 Rationalize the risk of antibiotics overuse
More informationSelective toxicity. Antimicrobial Drugs. Alexander Fleming 10/17/2016
Selective toxicity Antimicrobial Drugs Chapter 20 BIO 220 Drugs must work inside the host and harm the infective pathogens, but not the host Antibiotics are compounds produced by fungi or bacteria that
More informationAntimicrobial utilization: Capital Health Region, Alberta
ANTIMICROBIAL STEWARDSHIP Antimicrobial utilization: Capital Health Region, Alberta Regionalization of health care services in Alberta began in 1994. In the Capital Health region, restructuring of seven
More informationChapter 51. Clinical Use of Antimicrobial Agents
Chapter 51 Clinical Use of Antimicrobial Agents History of antimicrobial therapy Early 17 th century Cinchona bark was used as an important historical remedy against malaria. 1909 Paul Ehrlich sought a
More informationAmoxicillin Introduction: Mechanism of action: Pharmacology: Indications: Dosage: 12 Weeks ( 3 Months):
Amoxicillin Introduction: A semisynthetic antibiotic, an analog of ampicillin, with a broad spectrum of bactericidal activity against many gram-positive and gram-negative microganisms. Mechanism of action:
More informationEuropean Committee on Antimicrobial Susceptibility Testing
European Committee on Antimicrobial Susceptibility Testing Routine and extended internal quality control as recommended by EUCAST Version 5.0, valid from 015-01-09 This document should be cited as "The
More informationStanding Orders for the Treatment of Outpatient Peritonitis
Standing Orders for the Treatment of Outpatient Peritonitis 1. Definition of Peritonitis: a. Cloudy effluent. b. WBC > 100 cells/mm3 with >50% polymorphonuclear (PMN) cells with minimum 2 hour dwell. c.
More informationGuidelines for Laboratory Verification of Performance of the FilmArray BCID System
Guidelines for Laboratory Verification of Performance of the FilmArray BCID System Purpose The Clinical Laboratory Improvement Amendments (CLIA), passed in 1988, establishes quality standards for all laboratory
More informationجداول میکروارگانیسم های بیماریزای اولویت دار و آنتی بیوتیک های تعیین شده برای آزمایش تعیین حساسیت ضد میکروبی در برنامه مهار مقاومت میکروبی
جداول میکروارگانیسم های بیماریزای اولویت دار و آنتی بیوتیک های تعیین شده برای آزمایش تعیین حساسیت ضد میکروبی در برنامه مهار مقاومت میکروبی ویرایش دوم بر اساس ed., 2017 CLSI M100 27 th تابستان ۶۹۳۱ تهیه
More informationPierre-Louis Toutain, Ecole Nationale Vétérinaire National veterinary School of Toulouse, France Wuhan 12/10/2015
Antimicrobial susceptibility testing for amoxicillin in pigs: the setting of the PK/PD cutoff value using population kinetic and Monte Carlo Simulation Pierre-Louis Toutain, Ecole Nationale Vétérinaire
More informationFinal Report. Project code: P.PSH.0653 Prepared by: Fiona Cotter Troy Laboratories Pty Ltd Date published: July 2014
Final Report Project code: P.PSH.0653 Prepared by: Fiona Cotter Troy Laboratories Pty Ltd Date published: July 2014 PUBLISHED BY Meat & Livestock Australia Limited Locked Bag 991 NORTH SYDNEY NSW 2059
More informationTherios 300 mg and 750 mg Palatable Tablets for Dogs
Ceva Animal Health Ltd Telephone: 01494 781510 Website: www.ceva.com Email: cevauk@ceva.com Therios 300 mg and 750 mg Palatable Tablets for Dogs Species: Therapeutic indication: Active ingredient: Product:
More information2016 Antibiotic Susceptibility Report
Fairview Northland Medical Center and Elk River, Milaca, Princeton and Zimmerman Clinics 2016 Antibiotic Susceptibility Report GRAM-NEGATIVE ORGANISMS 2016 Gram-Negative Non-Urine The number of isolates
More informationAuthor - Dr. Josie Traub-Dargatz
Author - Dr. Josie Traub-Dargatz Dr. Josie Traub-Dargatz is a professor of equine medicine at Colorado State University (CSU) College of Veterinary Medicine and Biomedical Sciences. She began her veterinary
More informationJAC Bactericidal index: a new way to assess quinolone bactericidal activity in vitro
Journal of Antimicrobial Chemotherapy (1997) 39, 713 717 JAC Bactericidal index: a new way to assess quinolone bactericidal activity in vitro Ian Morrissey* Department of Biosciences, Division of Biochemistry
More informationMicrobiology ( Bacteriology) sheet # 7
Microbiology ( Bacteriology) sheet # 7 Revision of last lecture : Each type of antimicrobial drug normally targets a specific structure or component of the bacterial cell eg:( cell wall, cell membrane,
More informationamoxycillin/clavulanate vs placebo in the prevention of infection after animal
Archives of Emergency Medicine, 1989, 6, 251-256 A comparative double blind study of amoxycillin/clavulanate vs placebo in the prevention of infection after animal bites P. H. BRAKENBURY & C. MUWANGA Accident
More information